The going-concern warning and massive dilutive offering signal acute financial distress. Monitor for a reverse stock split to regain Nasdaq bid-price compliance by Dec 28, 2026, and for any covenant breach on the OrbiMed loan facility. Further equity or debt raises are likely given the cash burn rate.
Price Chart
Executive Summary
MDxHealth reported H1 2026 revenue of $51.1M (+14% YoY), but the growth is entirely from the ExoDx acquisition — organic tissue-based revenue declined 12% to $38.1M. Operating loss more than doubled to $13.3M, net loss widened to $20.4M, and the company issued a going-concern warning citing material uncertainty. A subsequent $20M dilutive equity offering at $0.454/share (86% dilution) and the Delta Lab Assignment for the Benefit of Creditors underscore severe financial distress. The stock remains non-compliant with Nasdaq's minimum bid price requirement (deadline Dec 28, 2026).
Key Facts
- Revenue from continuing operations grew 14% to $51.1M, but tissue-based (core) revenue fell 12% to $38.1M; liquid-based revenue from ExoDx jumped to $12.8M
- Operating loss widened 113% to $13.3M; net loss from continuing ops increased 18% to $19.2M
- Gross margin contracted 420bps to 63.7% due to test mix shift
- Going-concern warning: accumulated deficit of $423.4M, negative equity of $30.4M, and net cash used in operations of $7.3M in H1
- Completed $20M registered direct placement of 44.1M shares at $0.454/share on Aug 13, 2026 — ~86% dilution from June 30 share count
- Delta Lab subsidiary executed an Assignment for the Benefit of Creditors on Aug 3, 2026; deconsolidation expected in Q3
- Nasdaq bid price non-compliance (below $1.00); compliance deadline Dec 28, 2026; MVLS requirement regained on Aug 28
- Cash and cash equivalents fell to $19.2M at June 30 from $29.0M at Dec 31, 2025
Financial Impact
Revenue $51.1M (+14%), operating loss $13.3M (+113%), net loss $20.4M (+23%), $20M dilutive equity offering at $0.454/share (86% dilution), cash burn $7.3M in H1
Risk Factors
- Nasdaq delisting if bid price not cured by Dec 28, 2026
- Further dilution from additional capital raises or warrant exercises
- Inability to achieve profitability or positive cash flow
- Covenant breach on $100M OrbiMed credit facility
- Delta Lab ABC may result in unexpected liabilities or legal costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (MDXH) — Batch item 1 | 0001213900-26-097170 |
| Document: ea0304284-6k_mdxhealth.htm | 0001213900-26-097170 |
| Document: 0001213900-26-097170-index-headers.html | 0001213900-26-097170 |
| Document: 0001213900-26-097170-index.html | 0001213900-26-097170 |
| Document: 0001213900-26-097170.txt | 0001213900-26-097170 |
| 6-K Filing (MDXH) — Batch item 6 | 0001213900-26-097170 |
| Document: ea0304284-6k_mdxhealth.htm | 0001213900-26-097170 |
| Document: 0001213900-26-097170-index-headers.html | 0001213900-26-097170 |
| Document: 0001213900-26-097170-index.html | 0001213900-26-097170 |
| Document: 0001213900-26-097170.txt | 0001213900-26-097170 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $0.2070 $0.1830 | ▲ +11.59% | ▲ +11.69% | $0.1900 (+8.21%) |
Oct 15, 2026 10d ago | SC 13D/A | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1900 (+8.03%) |
Oct 15, 2026 10d ago | Press Release | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1900 (+8.03%) |
Sep 17, 2026 5w ago | 144 | $0.6300 $0.5650 | ▲ +10.32% | ▲ +11.59% | $0.1900 (+69.84%) |
Sep 3, 2026 7w ago | 6-K | $0.7484 $0.7072 | ▲ +5.51% | ▲ +4.30% | $0.1900 (+74.61%) |
Aug 13, 2026 10w ago | 6-K | $0.8080 $0.7431 | ▲ +8.03% | ▲ +6.66% | $0.1900 (+76.49%) |
Aug 13, 2026 10w ago | Press Release | $0.8080 $0.7431 | ▼ −8.03% | ▼ −6.66% | $0.1900 (−76.49%) |
Jul 24, 2026 13w ago | 6-K | $0.4180 $0.4180 | · 0.00% | ▲ +1.07% | $0.1900 (+54.55%) |
Jul 2, 2026 16w ago | Press Release | $0.4765 $0.4899 | ▼ −2.81% | ▼ −1.88% | $0.1900 (+60.13%) |
Apr 29, 2026 25w ago | 6-K | $2.04 $2.01 | ▼ −1.47% | ▼ −3.20% | $0.1900 (−90.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers